RecruitingType 1 Diabetes

Registry for Stage 2 Type 1 Diabetes

Eligible age

All ages

Accepts

All genders

Locations

20 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general information on patients with stage 2 T1D and further information on the long-term effects of TZIELD® in patients with Stage 2 T1D, treated as per standard of care.

Sponsor: Sanofi

You may qualify if…

✓ TZIELD-Exposed Cohort
✓ Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
✓ Day 1: 65 mcg/m2
✓ Day 2: 125 mcg/m2
✓ Day 3: 250 mcg/m2
✓ Day 4: 500 mcg/m2
✓ Days 5 through 14: 1,030 mcg/m2 per day
✓ Cumulative dose is approximately 11,240 mcg/m2

You may not qualify if…

✕ Patients who initiated TZIELD treatment more than 6 months prior to enrollment
✕ Patients who had participated in a previous clinical trial for TZIELD
✕ Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled
✕ The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.